Latest Articles
Oriva: Targeting the endometriosis trifecta - biocentury.com
Oriva: Targeting the endometriosis trifecta biocentury.com
Published: July 16, 2026, 12:14 a.m.
Oriva: Targeting the endometriosis trifecta - BioCentury
Oriva: Targeting the endometriosis trifecta BioCentury
Published: July 16, 2026, 12:14 a.m.
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) - markets.businessinsider.com
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) markets.businessinsider.com
Published: June 24, 2026, 11:25 a.m.
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) - The Manila Times
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) The Manila Times
Published: June 24, 2026, 10:48 a.m.
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 - riauone.com
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 riauone.com
Published: June 15, 2026, 12:29 p.m.
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 - The Manila Times
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 The Manila Times
Published: June 14, 2026, 10:21 p.m.
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 - NTB Kommunikasjon
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 NTB Kommunikasjon
Published: June 14, 2026, 10:05 p.m.
ABSI: ABS-201 advances in phase II trials, targeting major unmet needs in hair loss and endometriosis - TradingView
ABSI: ABS-201 advances in phase II trials, targeting major unmet needs in hair loss and endometriosis TradingView
Published: June 9, 2026, 8:01 p.m.
Maipl Therapeutics Advances Non-Hormonal Oral Endometriosis Therapy Targeting Prostaglandin F2α Receptor - Femtech Insider
Maipl Therapeutics Advances Non-Hormonal Oral Endometriosis Therapy Targeting Prostaglandin F2α Receptor Femtech Insider
Published: May 15, 2026, 11:33 a.m.
Endometriosis Has a Metabolism Problem, and Targeting It Could Transform Treatment - The American Journal of Managed Care® (AJMC®)
Endometriosis Has a Metabolism Problem, and Targeting It Could Transform Treatment The American Journal of Managed Care® (AJMC®)
Published: May 8, 2026, 4:51 p.m.
Link copied to clipboard!